Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2009: Volume 14/ Issue 36 Article 2
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 14, Issue 36, 10 September 2009
Rapid communications
Imported human African trypanosomiasis in Europe, 2005-2009
  1. Infectious and Tropical Disease Unit, Hôpital Nord AP-HM, Marseille, France
  2. Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
  3. Infectious and Tropical Disease Unit, Hôpital Pitié-Salpêtrière, Paris, France
  4. Infectious and Tropical Disease Unit, Military Hospital Lavéran, Marseille, France
  5. Oslo University Hospital, Ullevål, Department of Infectious Diseases, Oslo, Norway
  6. Division of International and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland
  7. Zurich University, WHO collaborative Centre for Travel Medicine, Zurich, Switzerland
  8. Infectious and Tropical Disease Unit, University of Brescia, Brescia, Italy
  9. Traveler Health Clinic, Wiliam C. Gorgas Center for Geographic Medicine, Division of Infectious Diseases, University of Alabama, Birmingham, United States
  10. Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
  11. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
  12. ECDC collaborative network for travel and tropical medicine: http://www.istm.org/eurotravnet/main.html

Citation style for this article: Gautret P, Clerinx J, Caumes E, Simon F, Jensenius M, Loutan L, Schlagenhauf P, Castelli F, Freedman D, Miller A, Bronner U, Parola P, for EuroTravNet. Imported human African trypanosomiasis in Europe, 2005-2009. Euro Surveill. 2009;14(36):pii=19327. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19327
Date of submission: 24 August 2009

Physicians in Europe are likely to see more African trypanosomiasis cases because of the increasing popularity of travel to Africa. In this paper the literature on imported cases in Europe, since 2005 is reviewed. Because of the high mortality risk associated with acute Rhodesian trypanosomiasis, travellers should be informed about preventive measures and the early disease manifestations.


Introduction

Human African trypanosomiasis (HAT) is endemic in sub-Saharan Africa. Trypanosoma brucei rhodesiense (East Africa) and T. b. gambiense (West Africa) are transmitted to humans by tsetse flies of the Glossina morsitans group (T. b. rhodesiense) and of the G. palpalis group (T. b. gambiense) which are found only in Africa. West African sleeping sickness has almost exclusively a human reservoir, while East African trypanosomiasis is a zoonosis involving antelopes, cattle and humans. Infections by both T. b. gambiense and T. b. rhodesiense are generally under-reported in humans due to acuteness and lack of specific symptoms at the onset of disease as well as its rural distribution. T. b. rhodesiense is focally endemic in many eastern and southern African countries. It tends to occur in form of epidemic outbursts. Human infections have been reported mainly from Malawi, south-east and central Uganda and Tanzania, and sporadically from Kenya, Mozambique, Rwanda, Zambia and Zimbabwe. T. b. gambiense, the parasite causing West African sleeping sickness is focally endemic in Angola, Democratic Republic of the Congo, Central African Republic, Chad, Republic of the Congo, Côte d’Ivoire, Guinea, southern Sudan and north-west Uganda. Cases have been sporadically reported from Burkina Faso, Cameroon, Equatorial Guinea, Gabon, Nigeria, Benin, Ghana and Mali [1]. All countries listed so far have a surveillance system for HAT, however, there is no dedicated structure for surveillance in Burundi, Ethiopia, Gambia, Guinea-Bissau, Liberia, Niger, Senegal and Sierra Leone, where under-reporting may be likely [2]. A new HAT atlas initiative for sub-Saharan Africa has led to the creation of a geographic database to store and regularly update HAT epidemiological data. The resulting detailed, high quality regional level maps allow the geo-location of autochtonous cases that have been detected through active and passive surveillance [3].

HAT has always been an exceptional travel-associated disease. It is a rare cause of fever [4] cutaneous lesions and/or neurological signs in travellers returning from endemic areas. Although it has been estimated that about 50 cases are reported yearly outside Africa [5], no recent estimate is available. In Europe, the largest published data on imported HAT included 109 cases registered between 1904 and 1963 [6]. Over the last decades, 26 cases (including 24 West African HAT) seen in France between 1980 and 2004, were reviewed [7]. In addition, imported cases were reported in Italy [8,9], Spain [10], the United Kingdom [11-13], Germany [14], the Netherlands [15-19], Belgium [20], Norway and Sweden [21,22], Switzerland [23], Poland [24] and France [25-26].

We present the clinical and epidemiological characteristics of published HAT cases imported in Europe since 2005 (Table).

Table. Imported cases of African trypanosomiasis in Europe, since 2005, by date of publication



Diagnosis

T. b. gambiense represents more than 90% of all reported cases of HAT worldwide (autochthonous and imported cases) but T. b. rhodesiense accounts for 60% of imported cases. T. b. rhodesiense infection in humans is characterised by high grade fever, an inoculation chancre and substantial parasitaemia in its acute stage. Incubation period is about 6 to 10 days, but may be as short as three days. Gambian HAT may follow an indolent course with a very low or absent parasitaemia. It may remain unrecognised for years [5]. T. b. gambiense is better adapted to its human host, allowing humans to be infective for extended periods thereby sustaining its endemicity. In active infection, T. b. gambiense and T. b. rhodesiense specific IgG and IgM antibodies are present in high concentration and can be detected by ELISA or immunofluorescence from about three to four weeks after infection. Parasite detection using blood concentration techniques should be done to confirm the infection. Furthermore, in 60% of infections with T. b. gambiense, parasites can be detected in lymph aspirate from enlarged cervical nodes. Cerebrospinal fluid examination is always required to evaluate neurological involvement which determines the choice of therapy [5].

Implications for travellers

Whereas imported HAT due to T. b. gambiense is more often seen in migrants and expatriates residing in rural endemic areas, HAT due to T. b. rhodesiense is more likely to be seen in travellers to East African game parks where the ungulate wildlife serves as a reservoir for the pathogen. In recent years almost all reported cases have been infected in northern Tanzania (Serengeti, Tarangire) or in Uganda (Queen Elizabeth National Park) [17,18,22,24,28]. Some emerging tourist destinations (Malawi: Kasungu National Park, Waza Game Reserve; Rwanda: Akagera National Park; Zambia: South Luangwa National Reserve; Tanzania: Moyowosi Game Reserve) are known foci of T. b. rhodesiense, and may pose a risk for travellers.

In travellers infected with T. b. rhodesiense, an evolving chancre on the bite site precedes the onset of high grade fever, and usually persists for a few days thereafter. This is an important clinical sign not to be missed by the attending physician. Fulminant disease progression has been reported in a German tourist in her forties with a history of tsetse bites during a visit to the Serengeti National Park. She died only six days after fever onset (13 days following tsetse bites), in Nairobi Hospital, after air ambulance evacuation from a private clinic in Dar es Salaam where the HAT diagnosis was made. She had two typical chancres that were missed when she first presented with fever in another clinic seven days after the tsetse bites, and a malaria diagnosis was alleged [29]. A history of tsetse fly bites in patients with clinical symptoms has to be considered a medical emergency. Early treatment with suramin (Germanin®, Bayer 205) or in case of non-availability, with pentamidine is essential to prevent severe complications and death. All available drugs for HAT treatment, including suramin can be obtained through the World Health Organization (WHO) trypanosomiasis control and surveillance unit, by contacting Dr. Simarro (simaropp@who.int) and Dr. Franco (francoj@who.int). A small stock of HAT drugs should be made available at one tropical medicine/travel medicine centre per country, in order to enable early treatment when required.

Conclusions

Physicians in Europe are likely to see more HAT cases because of the increasing popularity of travel to Africa, the only region that has recorded a growing number (3%) of tourist arrivals in 2009 according to the United Nations World Tourism Organization (UNWTO, www.unwto.org). The average annual growth of tourism in some sub-Saharan countries such as Tanzania and Uganda has ranged between 10 and 20% with a focus on safari travel. Because of the high mortality risk associated with acute Rhodesian trypanosomiasis, European travellers to destinations where the disease is endemic, particularly game parks and safari areas in eastern and southern Africa, should be informed about the early disease manifestations and advised to report tsetse bites to their physician upon return, when presenting symptoms. Although thousands of travellers are bitten by tsetse flies each year, the majority will not develop HAT. Nevertheless, caution is recommended. Preventive measures against tsetse fly bites are helpful. The tsetse fly is active during the daytime and is particularly attracted by motion and dark colours, with a marked preference for blue. Bites are painful and can be prevented by wearing wrist- and ankle-length clothing of thick material and avoiding bright or contrasting coloured clothing. Because the tsetse fly is able to bite through thinly woven fabric, the impregnation of clothing with permethrin is recommended together with the application of a skin repellent [30].

At present, imported HAT cases are not systematically reported through the existing channels to signal emerging infections (ProMED) or in the accessible medical literature. To harmonise reporting, we would recommend the creation of an electronic reporting form. This would allow for the evaluation of long term trends in imported HAT, and contribute to identifying risk factors and risk areas.


 References

  1. World Health Organization. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rec. 2006;81(8):71-80.
  2. World Health Organization. Human African Trypanosomiasis. Annual number of cases reported to WHO, 2000-2007. Map. Available from: http://www.who.int/trypanosomiasis_african/disease/en/index.html  
  3. Cecchi G, Paone M, Franco JR, Fèvre EM, Diarra A, Ruiz JA, et al. Towards the atlas of Human African trypanosomiasis. Int J Health Geogr. 2009;8:15.
  4. Bottieau E, Clerinx J, Schrooten W, Van den Enden E, Wouters R, Van Esbroeck M, et al. Etiology and outcome of fever after a stay in the tropics. Arch Intern Med. 2006;166:1642-8.
  5. Lejon V, Boelaert M, Jannin J, Moore A, Buscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect Dis. 2003;3(12):804-8.
  6. Duggan AJ, Hutchinson MP. Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg. 1966;69(6):124-31.
  7. Legros F, Ancelle T, réseau Anofel. Trypanosomiase humaine africaine: recensement des cas d’importation observés en France, 1980-2004 [Human African trypanosomiasis: review of imported cases observed in France, 1980-2004]. Bulletin Epidémiologique Hebdomadaire. 2006;7:57-59. French.
  8. Ripamonti D, Massari M, Arici C, Gabbi E, Farina C, Brini M, et al. African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. Clin Infect Dis. 2002;34(1):E18-E22.
  9. Bisoffi Z, Beltrame A, Monteiro G, Arzese A, Marocco S, Rorato G, et al. African trypanosomiasis gambiense, Italy. Emerg Infect Dis. 2005;11(11):1745-7.
  10. Grau Junyent JM, Rozman M, Corachan M, Estruch R, Urbano-Marquez A. An unusual course of west African trypanosomiasis in a Caucasian man. Trans R Soc Trop Med Hyg. 1987;81(6):931-2.
  11. Scott JA, Davidson RN, Moody AH, Bryceson AD. Diagnosing multiple parasitic infections: trypanosomiasis, loiasis and schistosomiasis in a single case. Scand J Infect Dis. 1991;23(6):777-80.
  12. Croft AM, Kitson MM, Jackson CJ, Minton EJ, Friend HM. African trypanosomiasis in a Britsh soldier. Mil Med. 2007;172(7):765-9.
  13. Checkley AM, Pepin J, Gibson WC, Taylor MN, Jager HR, Mabey DC. Human African trypanosomiasis: diagnosis, relapse and survival after severe melarsoprol-induced encephalopathy. Trans R Soc Trop Med Hyg. 2007;101(5):523-6.
  14. Löscher T, Nothdurft HD, Taelman H, Boogaerts M, Omar M, von Sonnenburg F. [Sleeping sickness in German travelers to the tropics]. Dtsch Med Wochenschr. 1989 Aug 4;114(31-32):1203-6. German.
  15. Otte JA, Nouwen JL, Wismans PJ, Beukers R, Vroon HJ, Stuiver PC. [African sleeping sickness in The Netherlands]. Ned Tijdschr Geneeskd. 1995;139(41):2100-4. Dutch.
  16. Mendonça Melo M, Rasica M, van Thiel PP, Richter C, Kager PA, Wismans PJ. [Three patients with African sleeping sickness following a visit to Tanzania]. Ned Tijdschr Geneeskd. 2002;146(52):2552-6. Dutch.
  17. Braakman HM, van de Molengraft FJ, Hubert WW, Boerman DH. Lethal African trypanosomiasis in a traveler: MRI and neuropathology. Neurology. 2006;66(7):1094-6.
  18. Jelinek T, Vlisser L. Trypanosomiasis – Netherland ex Tanzania (Serengeti). ProMED-mail post. 20090724.2613. Available from: http://www.promedmail.org/pls/otn/f?p=2400:1202:3338266703010071::NO::F2400_P1202_CHECK_DISPLAY,F2400_P1202_PUB_MAIL_ID:X,78467
  19. Kager PA, Schipper HG, Stam J, Majoie CB. Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature.Am J Trop Med Hyg. 2009;80(6):947-52.
  20. Buyse D, Van den Ende J, Vervoort T, Van den Enden E. [Sleeping sickness as an import pathology following a stay in Zaire]. Acta Clin Belg. 1996;51(6):409-11. Dutch.
  21. Bakken JS, Arroe M. [African trypanosomiasis. Report on a patient]. Tidsskr Nor Laegeforen. 1985;105(23):1501-2. Norwegian.
  22. Jelinek T, Bisoffi Z, Bonazzi L, van Thiel P, Bronner U, de Frey A, et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis. 2002;8(6):634-5.
  23. Braendli B, Dankwa E, Junghanss T. [East African sleeping sickness (Trypanosoma rhodesiense infection) in 2 Swiss travelers to the tropics]. Schweiz Med Wochenschr. 1990;120(37):1348-52. German.
  24. Paul M. Trypanosomiasis – Poland ex Uganda (Queen Elizabeth national park). ProMED-mail post. 20090810.2844. Available from: http://www.promedmail.org/pls/otn/f?p=2400:1202:3338266703010071::NO::F2400_P1202_CHECK_DISPLAY,F2400_P1202_PUB_MAIL_ID:X,78740
  25. Iborra C, Danis M, Bricaire F, Caumes E. A traveler returning from Central Africa with fever and a skin lesion. Clin Infect Dis. 1999;28(3):679-80.
  26. Ezzedine K, Darie H, Le Bras M, Malvy D. Skin features accompanying imported human African trypanosomiasis: hemolymphatic Trypanosoma gambiense infection among two French expatriates with dermatologic manifestations. J Travel Med. 2007;14(3):192-6.
  27. Hope-Rapp E, Moussa Coulibaly O, Klement E, Danis M, Bricaire F, Caumes E. [Double trypanosomal chancre revealing West African trypanosomiasis in a Frenchman living in Gabon]. Ann Dermatol Venereol. 2009;136(4):341-5. French.
  28. Callens S, van Wijngaerden E, Clerinx J, Colebunders R. [Three patients with African sleeping sickness following a visit to Tanzania]. Ned Tijdschr Geneeskd. 2003;147(12):581. Dutch.
  29. Klaassen B, Smit YG. [A fatal outcome of acute East African sleeping sickness in Tanzania]. Tijdschr Infect. 2009;4(2):61-5. Dutch.
  30. Sholdt LL, Schreck CE, Mwangelwa MI, Nondo J, Siachinji VJ. Evaluations of permethrin-impregnated clothing and three topical repellent formulations of deet against tsetse flies in Zambia. Med Vet Entomol. 1989;3(2):153-8.


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.